Full Text
Alemtuzumab Is The Most Cost-Effective Option In Comparison To Available Therapies In The Treatment of Rrms From The UK NHS Perspective

Abstract

Authors

D Rog JD Guo A Nucit G Le Bagousse-Bego M Chevli L Chung

Back to Volume 20, Issue 9
Your browser is out-of-date

ISPOR recommends that you update your browser for more security, speed and the best experience on ispor.org. Update my browser now

×